Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions

Pharmacotherapy

Volumn 29, Issue 7, 2009, Pages 822-831

  Thomas, Kelan L H ^a   Ellingrod, Vicki L ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Adverse drug reactions; Antidepressants; Pharmacogenetics; Selective serotonin reuptake inhibitor; SSRI

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; ANTIDEPRESSANT AGENT; CITALOPRAM; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DOPAMINE RECEPTOR; FLUOXETINE; FLUVOXAMINE; GLUTAMATE RECEPTOR; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; SEROTONIN 2A RECEPTOR; SEROTONIN 3B RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRYPTOPHAN HYDROXYLASE;

ADVERSE DRUG REACTION; AGITATION; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; INSOMNIA; MEDICAL PERSONNEL; MENTAL DISEASE; NAUSEA; PHARMACOGENETICS; PHARMACOGENOMICS; PROMOTER REGION; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDAL IDEATION; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MENTAL DISORDERS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SEROTONIN UPTAKE INHIBITORS;

EID: 67650783189     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.7.822     Document Type: Review

References (36)

1. IMS Health Inc. 2007 top 10 therapeutic classes by U.S. dispensed prescriptions. IMS national prescription audit plus. Available from http://www1.imshealth.com/ims/portal/front/ articleC/0,2777,6599-80411808- 80413635,00.html. Accessed September 10, 2008.
2. Serretti A, Artioli P. The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenomics J 2004;4(4):233-244 (Pubitemid 39136766)
3. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP working group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med 2007;9(12):819-825
4. Lesch KP, Gutknect L. Pharmacogenetics of the serotonin transporter. Prog Neuropsychopharmacol Biol Psychiatry 2005;29(6):1062-1073
5. Greenberg BD, Tolliver TJ, Huang SJ, Li Q, Bengel D, Murphy DL. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet 1999;88(1):83-87 (Pubitemid 29075327)
6. Kaiser R, Müller-Oerlinghausen B, Filler D, et al. Correlation between serotonin uptake in human blood platelets with the 44-bp polymorphism and the 17-bp variable number of tandem repeat of the serotonin transporter. Am J Med Genet 2002;114(3):323-328 (Pubitemid 34258860)
7. Takahashi H, Yoshida K, Ito K, et al. No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment. Eur Neuropsychopharmacol 2002;12(5):477-481
8. Perlis RH, Mischoulon D, Smoller JW, et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 2003;54(9):879-883 (Pubitemid 37311349)
9. Putzhammer A, Schoeler A, Rohrmeier T, Sand P, Hajak G, Eichhammer P. Evidence of a role for the 5-HTTLPR genotype in the modulation of motor response to antidepressant treatment. Psychopharmacology (Berl) 2005;178(2-3):303-308 (Pubitemid 40379225)
10. Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004;61(11):1163-1169 (Pubitemid 39463418)
11. Ng CH, Easteal S, Tan S, Schweitzer I, Ho BK, Aziz S. Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(5):953-957 (Pubitemid 43795359)
12. Kato M, Fukuda T, Wakeno M, et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 2006;53(4):186-195 (Pubitemid 44252779)
13. Hedenmalm K, Güzey C, Dahl ML, Yue QY, Spigset O. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol 2006; 26(2):192-197 (Pubitemid 43740346)
14. Tanaka M, Kobayashi D, Murakami Y, et al. Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. Int J Neuropsychopharmacol 2008;11(2):261-267 (Pubitemid 351231828)
15. Smits K, Smits L, Peeters F, et al. Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 2007;22(3):137-143 (Pubitemid 46559869)
16. Hu XZ, Rush AJ, Charney D, et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 2007;64(7):783-792 (Pubitemid 47026374)
17. Stahl S. Essential psychopharmacology: neuroscientific basis and practical applications. New York: Cambridge University Press, 2000.
18. Murphy GM Jr, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003;160(10):1830-1835
19. Polesskaya OO, Sokolov BP. Differential expression of the "C" and "T" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res 2002;67(6):812-822
20. Yoshida K, Naito S, Takahashi H, et al. Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine. Neuropsychobiology 2003;48(1):10-13. (Pubitemid 36928708)
21. Suzuki Y, Sawamura K, Someya T. Polymorphisms in the 5- hydroxytryptamine 2A receptor and cytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in Japanese depressed patients. Neuropsychopharmacology 2006;31(4):825-831
22. Bishop JR, Moline J, Ellingrod VL, Schultz SK, Clayton AH. Serotonin 2A-1438 G/A and G-protein beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology 2006;31(10): 2281-2288 (Pubitemid 44413208)
23. Sugai T, Suzuki Y, Sawamura K, Fukui N, Inoue Y, Someya T. The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. Pharmacogenomics J 2006;6(5):351-356 (Pubitemid 44480155)
24. Niesler B, Flohr T, Nöthen MM, et al. Association between the 5′ UTR variant C178T of the serotonin receptor gene HTR3A and bipolar affective disorder. Pharmacogenetics 2001;11(6): 471-475 (Pubitemid 32778225)
25. Frank B, Niesler B, Nöthen MM, et al. Investigation of the human serotonin receptor gene HTR3B in bipolar affective and schizophrenic patients. Am J Med Genet B Neuropsychiatr Genet 2004;131B(1):1-5. (Pubitemid 39458429)
26. Tremblay PB, Kaiser R, Sezer O, et al. Variations in the 5- hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 2003;21(11):2147-2155 (Pubitemid 46606363)
27. Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 2001;6(5):586-592 (Pubitemid 32772568)
28. Thompson J, Thomas N, Singleton A, et al. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997;7(6):479-484 (Pubitemid 27517576)
29. Laje G, Paddock S, Manji H, et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 2007;164(10):1530-1538 (Pubitemid 350069732)
30. Balciuniene J, Emilsson L, Oreland L, Pettersson U, Jazin E. Investigation of the functional effect of monoamine oxidase polymorphisms in human brain. Hum Genet 2002;110(1):1-7. (Pubitemid 36067410)
31. Perlis RH, Purcell S, Fava M, et al. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry 2007;64(6):689-697 (Pubitemid 46878669)
32. Perlis RH, Holt DJ, Smoller JW, et al. Association of a polymorphism near CREB1 with differential aversion processing in the insula of healthy participants. Arch Gen Psychiatry 2008;65(8):882-892
33. Roberts RL, Mulder RT, Joyce PR, Luty SE, Kennedy MA. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Hum Psychopharmacol 2004;19(1):17-23. (Pubitemid 38159271)
34. Gerstenberg G, Aoshima T, Fukasawa T, et al. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology (Berl) 2003;167(4):443-448 (Pubitemid 36754247)
35. Yin OQ, Wing YK, Cheung Y, et al. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients. J Clin Psychopharmacol 2006;26(4):367-372 (Pubitemid 44192092)
36. Uhr M, Tontsch A, Namendorf C, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008;57(2):203-209